Document is current
Any future updates will be listed below
-
Authors
Brod, Meryl https://orcid.org/0000-0002-0663-5838
Bushnell, Donald M.
Neergaard, Jesper Skov
Waldman, Laura Tesler
Busk, Anne Kirstine
-
Funding
Funding for this research was provided by:
Novo Nordisk
- License Information
-
More Information
Article History
Received: 11 April 2022
Accepted: 16 January 2023
First Online: 23 February 2023
Declarations
:
: IRB approval was obtained for the development of the Hemo-TEM Copernicus Group Independent Review Board (#TBG1-16–077).
: Not applicable.
: MB and DBM are consultants to the pharmaceutical industry, including Novo Nordisk. LTW was a consultant to the pharmaceutical industry during the time this research was conducted. AKB is an employee and shareholder of Novo Nordisk A/S and JSN is an employee of Novo Nordisk A/S.
